Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$2.55 - $4.1 $36,816 - $59,195
-14,438 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$2.5 - $3.42 $93,500 - $127,908
-37,400 Reduced 72.15%
14,438 $40,000
Q4 2021

Feb 14, 2022

SELL
$2.88 - $5.5 $13,536 - $25,850
-4,700 Reduced 8.31%
51,838 $154,000
Q3 2021

Nov 15, 2021

SELL
$3.57 - $5.6 $18,207 - $28,560
-5,100 Reduced 8.27%
56,538 $270,000
Q2 2021

Aug 16, 2021

BUY
$3.46 - $4.92 $165,865 - $235,854
47,938 Added 349.91%
61,638 $239,000
Q1 2021

May 17, 2021

BUY
$3.27 - $7.14 $11,772 - $25,704
3,600 Added 35.64%
13,700 $64,000
Q4 2020

Feb 16, 2021

SELL
$1.94 - $3.19 $50,870 - $83,648
-26,222 Reduced 72.19%
10,100 $31,000
Q3 2020

Nov 16, 2020

BUY
$1.79 - $3.3 $65,016 - $119,862
36,322 New
36,322 $88,000

Others Institutions Holding ANIX

About Anixa Biosciences Inc


  • Ticker ANIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,661,700
  • Market Cap $67.8M
  • Description
  • Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the...
More about ANIX
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.